MedTrace Logo

Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea

NCT04839549 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-06-18

No results posted yet for this study

Summary

To determine patient preference and treatment outcomes with an intracanalicular dexamethasone (0.4mg) insert compared to a standard steroid drop regimen in the contralateral eye for the treatment of ocular rosacea.

Conditions

  • Ocular Rosacea

Interventions

DRUG

Dextenza 0.4Mg Ophthalmic Insert

Dextenza 0.4Mg Ophthalmic Insert

DRUG

Fluoromethalone .01%

Fluoromethalone .01%

Sponsors & Collaborators

  • Eye Associates of Central Texas

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-06
Primary Completion
2022-11-29
Completion
2022-11-29
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839549 on ClinicalTrials.gov